000950 C.Q. Pharmaceutical Holding
- 4.68
- +0.07+1.52%
C.Q. Pharmaceutical Holding News
C.Q. Pharmaceutical's H1 Profit to Fall Up to 57%; Shares Down 3%
C.Q. Pharmaceutical Holding: 2024 Interim Performance Forecast
Express News | C.Q. Pharmaceutical Holding expects a year-on-year decrease of 49.38% to 57.17% in net income for the first half of the year.
C.Q. Pharmaceutical Holding (000950.SZ): Chairman Yuan Quan completed shareholding of 219,700 shares.
On June 27th, Gelunhui reported that C.Q. Pharmaceutical Holding (000950.SZ) has received a notice from Mr. Yuan Quan, the company's chairman, regarding the completion of the shareholding plan on June 27th, 2024. As of June 27th, 2024, the expiration date of the plan has been reached and the plan has been fully implemented. Mr. Yuan Quan has accumulated 219,700 shares of the company's stock, with a total amount of 992,227 yuan, accounting for 0.01% of the total share capital of the company. This shareholding plan has been fully implemented.
As of May 31st, the total number of shareholders of c.q. pharmaceutical holding (000950.SZ) was 40,349.
C.q. pharmaceutical holding (000950.SZ) stated on the investor interaction platform that as of May 31, 2024, the total number of shareholders of the company was 40,349.
Express News | Chongyao Group and Zhixiang Jintai have signed a global strategy cooperation agreement.
Express News | C.Q. Pharmaceutical Holding: China General Technology Group plans to acquire 2% equity of Chongqing Medicine. State-owned Assets Supervision and Administration Commission of the State Council will become the actual controller of the company.
Heavy Pharmaceutical Holdings (000950.SZ) 2023 equity distribution: 0.5 yuan for every 10 shares
Heavy Pharmaceutical Holdings (000950.SZ) issued an announcement. The company's 2023 equity distribution plan is: The company plan...
Heavy Pharmaceutical Holdings (000950.SZ): Expected to achieve annual revenue of 85-90 billion yuan
Gelonghui May 27丨Heavy Pharmaceutical Holdings (000950.SZ) was surveyed by a specific target on May 27, 2024, on “This year's business plan?” The company replied that in 2024, the company will take root in its main business and accelerate the development of various business segments. At the same time, under comprehensive circumstances such as operating capacity and future development plans, it is expected to achieve annual revenue of 85-90 billion yuan.
C.Q. Pharmaceutical Signs Cooperation Deal With JD.com; JD.com Drops 4%
Express News | Heavy Pharmaceutical Holdings: Signed a “Strategic Cooperation Framework Agreement” with JD Group
Express News | Tianfeng Securities: The pharmaceutical distribution sector is expected to usher in a valuation repair
Heavy Pharmaceutical Holdings (000950.SZ): Currently no business related to genetic sequencing
Gelonghui, May 9 | Heavy Pharmaceutical Holdings (000950.SZ) said on the investor interactive platform that the company's main business is wholesale and retail of pharmaceuticals and medical devices, and currently has no genetic sequencing business.
Heavy Pharmaceutical Holdings (000950): The company's operations are gradually improving, and the reform of state-owned enterprises continues to advance
Incident: The company achieved operating income of 80.119 billion yuan in 2023, +18.12% year on year; net profit to mother was 655 million yuan, or -31.22% year on year; net profit after deducting non-return to mother was 583 million yuan, -33 million yuan year on year
Heavy Pharmaceutical Holdings (000950): Western Pharmaceutical Distribution Leader Benefiting from National Reform
Key investment points: From the west to the leading pharmaceutical distribution company in the country, it is expected to benefit from the accelerated increase in the concentration of the pharmaceutical distribution industry in the context of state-owned enterprise reform and deepening medical reform. Under the current industry integration window, distribution companies are in a critical period of card positions
China Grants Drug Registration Certificate to C.Q. Pharmaceutical's Anti-Inflammatory Drug
Express News | Heavy Pharmaceutical Holdings: The holding subsidiary obtained a drug registration certificate
Heavy Medicine Holdings (000950.SZ): Tofacib citrate tablets obtained drug registration certificate
Heavy Pharmaceutical Holdings (000950.SZ) issued an announcement to change Chongqing Pharmaceutical (Group) Co., Ltd., a holding subsidiary of the company...
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Heavy Pharmaceutical Holdings (000950.SZ): Net profit of 103 million yuan in the first quarter decreased by 37.99% year-on-year
On April 26, Ge Longhui Holdings (000950.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 19.624 billion yuan, up 0.02% year on year; net profit attributable to shareholders of listed companies was 103 million yuan, down 37.99% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 92.481 million yuan, down 37.94% year on year; basic earnings per share were 0.06 yuan.
Analysis
Price Target
No Data
